Insights

Gathering insights about Akero…

Similar companies to Akero

Akero Tech Stack

Akero uses 8 technology products and services including Cloudinary, Cloudflare, Mailgun, and more. Explore Akero's tech stack below.

Cloudinary
Content Delivery Network
Cloudflare
Content Management System
Mailgun
Email
Polyfill
Javascript Libraries
PHP
Programming Languages
Google Tag Manager
Tag Management
Tailwind CSS
UI Frameworks
Facebook
Widgets

Media & News

Akero Therapeutics Presents New Analyses from Phase 2b SYMMETRY and HARMONY Trials of Efruxifermin at 76th Annual AASLD The Liver Meeting® 2025
Post-hoc analyses corroborate previously reported antifibrotic effects of efruxifermin observed in 96-week Phase 2b SYMMETRY trial and indicate potential to reduce risk of disease progression in compensated cirrhosis (F4c) due to MASH
Nov 07, 2025 | www.globenewswire.com
Berger Montague PC Investigates Akero Therapeutics, Inc. and Its Board of Directors for Breach of Fiduciary Duties and Violations of Federal Securities Laws (NASDAQ: AKRO)
PHILADELPHIA , Nov. 4, 2025 /PRNewswire/ -- Berger Montague PC advises shareholders of Akero Therapeutics, Inc. ("Akero" or the "Company") about an investigation into the Company and members of its Board of Directors for potential breaches of fiduciary duties and violations of the federal securities laws. Shareholders of Akero may learn more about this investigation by contacting Berger Montague: Andrew Abramowitz at aabramowitz@bergermontague.com or (215) 875-3015 or Radha Raghavan at rraghavan@bergermontague.com or (215) 875-4698, or CLICK HERE.
Nov 04, 2025 | www.prnewswire.com
Berger Montague PC Investigates Akero Therapeutics, Inc. and Its Board of Directors for Breach of Fiduciary Duties and Violations of Federal Securities Laws (NASDAQ: AKRO)
PHILADELPHIA , Oct. 29, 2025 /PRNewswire/ -- Berger Montague PC advises shareholders of Akero Therapeutics, Inc. ("Akero" or the "Company") about an investigation into the Company and members of its Board of Directors for potential breaches of fiduciary duties and violations of the federal securities laws. Shareholders of Akero may learn more about this investigation by contacting Berger Montague: Andrew Abramowitz at aabramowitz@bergermontague.com or (215) 875-3015 or Radha Raghavan at rraghavan@bergermontague.com or (215) 875-4698, or CLICK HERE.
Oct 29, 2025 | www.prnewswire.com
My Top 3 Pharma Stocks
Obesity, type 2 diabetes, and cancer continue to grow across the globe, but pharma stocks remain off the radars of many investors. Many of them consistently beat the Street's consensus estimates and offer dividend yields even higher than IT, as well as oil and gas stocks. In this article, I reveal my top 3 Big Pharma players.
Oct 20, 2025 | seekingalpha.com
Akero Therapeutics Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Akero Therapeutics, Inc. - AKRO
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Akero Therapeutics, Inc. (NasdaqGS: AKRO) to Novo Nordisk A/S. Under the terms of the proposed transaction, shareholders of Akero will receive $54.00 per share in cash, and a non-transferable Contingent Value Right entitling its holder to receive a cash payment of $6.00 per share upon full U.S. regu.
Oct 10, 2025 | www.businesswire.com
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Akero Therapeutics, Inc. (NASDAQ: AKRO)
NEW YORK, Oct. 10, 2025 (GLOBE NEWSWIRE) -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the “M&A Class Action Firm”), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2024 ISS Securities Class Action Services Report. The firm is headquartered at the Empire State Building in New York City and is investigating Akero Therapeutics, Inc. (NASDAQ: AKRO ) related to its sale to Novo Nordisk A/S. Under the terms of the proposed transaction, Akero shareholders will receive $54.00 per share in cash, and a non-transferable contingent value right entitling its holder to receive a cash payment of $6.00 per share upon full U.S. regulatory approval of efruxifermin by June 30, 2031. Is it a fair deal?
Oct 10, 2025 | www.globenewswire.com
Akero Therapeutics soars after Novo Nordisk set for $5.2B cash acquisition
Novo Nordisk said on Thursday it would acquire Akero Therapeutics for up to $5.2 billion in cash, marking a significant push into treatments for fatty liver disease as the Danish drugmaker seeks to broaden its pipeline beyond diabetes and obesity drugs. The deal sent Akero shares up by more than 17% in premarket trading, while
Oct 10, 2025 | invezz.com

Akero's Email Address Formats

Akero uses at least 1 format(s):

Akero Email Formats	Example	Percentage
First.Last@akerolabs.com	John.Doe@akerolabs.com	68%
FirstLast@akerolabs.com	JohnDoe@akerolabs.com	11%
First@akerolabs.com	John@akerolabs.com	10%
FirLast@akerolabs.com	JohDoe@akerolabs.com	11%

Frequently Asked Questions

Where is Akero's headquarters located?

Akero's main headquarters is located at 134 N. 4th St, Second Floor New York City, New York 11249, US. The company has employees across 2 continents, including EuropeNorth America.

What is Akero's stock symbol?

Akero is a publicly traded company; the company's stock symbol is AKRO.

What is Akero's official website and social media links?

Akero's official website is akerolabs.com and has social profiles on LinkedIn.

What is Akero's NAICS code?

Akero's NAICS code is 6113 - Colleges, Universities, and Professional Schools.

How many employees does Akero have currently?

As of October 2025, Akero has approximately 11 employees across 2 continents, including EuropeNorth America. Key team members include Chief Operating Officer: D. S.Head Of Conversion Solutions: J. P.Head Of Sales: S. S.. Explore Akero's employee directory with LeadIQ.

What industry does Akero belong to?

Akero operates in the Higher Education industry.

What technology does Akero use?

Akero's tech stack includes CloudinaryCloudflareMailgunPolyfillPHPGoogle Tag ManagerTailwind CSSFacebook.

What is Akero's email format?

Akero's email format typically follows the pattern of First.Last@akerolabs.com. Find more Akero email formats with LeadIQ.

When was Akero founded?

Akero was founded in 2019.

Akero

Higher EducationUnited States11-50 Employees

Seamlessly connect your digital marketing spend to your enrollment outcomes and visualize the whole student journey so you can increase enrollment and reduce costs.
Discover our top 3 products: 
- Campaigns:  AI powered student advertising with guaranteed results.
- Convert: Don't let your perfect students slip through your fingers with next gen forms and landing pages.
- Connect: Seamlessly intergrate with all major CRMS to get complete clarity on your recruitment funnel